Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters











Database
Language
Publication year range
1.
Neuroscience ; 138(4): 1205-13, 2006.
Article in English | MEDLINE | ID: mdl-16460878

ABSTRACT

Densely aggregated beta-amyloid peptides are believed to play a key role in the pathogenesis of Alzheimer's disease. Amyloid plaques are a potential target for molecular imaging to determine the clinical status of Alzheimer's disease. Phase-contrast X-ray imaging combined with computed tomography is a promising technique that can be used to visualize the physical density of structures in biological tissues non-invasively, and without the use of imaging agents. Using brain tissue isolated from a mouse model of Alzheimer's disease, we show that beta-amyloid 40-positive/beta-amyloid 42-positive amyloid plaques, but not beta-amyloid 40-negative/beta-amyloid 42-positive amyloid plaques, exist as high-density aggregates that can be specifically detected by phase-contrast X-ray computed tomography. The phase-contrast X-ray computed tomography detected beta-amyloid 40-positive/beta-amyloid 42-positive amyloid plaques in three-dimensions with an extremely high sensitivity comparable to that of histological analysis, and also enabled the load of amyloid plaques to be quantified. Furthermore, the use of phase-contrast X-ray computed tomography reveals that the physical density of beta-amyloid 40-positive/beta-amyloid 42-positive amyloid plaques increases with age, and that the large volume, high-density, amyloid plaques that are specifically observed in aged Alzheimer's disease mice are closely associated with neuritic dystrophy. These results demonstrate that phase-contrast X-ray computed tomography is a highly sensitive imaging technique for analyzing dense-cored amyloid plaques in postmortem samples, and is beneficial in elucidating amyloid pathophysiology in Alzheimer's disease.


Subject(s)
Alzheimer Disease/diagnostic imaging , Cerebral Cortex/diagnostic imaging , Cerebral Cortex/pathology , Plaque, Amyloid/diagnostic imaging , Plaque, Amyloid/pathology , Tomography, X-Ray Computed/methods , Aging/pathology , Alzheimer Disease/physiopathology , Amyloid beta-Peptides/metabolism , Animals , Cerebral Cortex/metabolism , Disease Models, Animal , Female , Mice , Mice, Transgenic , Microscopy, Phase-Contrast/methods , Neurites/metabolism , Neurites/pathology , Peptide Fragments/metabolism , Plaque, Amyloid/metabolism , Predictive Value of Tests
2.
Biochem Biophys Res Commun ; 255(2): 367-70, 1999 Feb 16.
Article in English | MEDLINE | ID: mdl-10049714

ABSTRACT

Dopamine D4-like binding sites are abundant in human cerebral cortex as detected by [3H]nemonapride. The extremely low density of D4 mRNA in human cerebral cortex is inconsistent with the high amount of D4-like binding sites. To investigate the nature of the D4-like receptors, [3H]nemonapride binding sites in the nonhuman primate cerebral cortex were characterized. Although [3H]nemonapride binding sites were D4-like, displaceable by clozapine but not raclopride, [3H]nemonapride binding was not displaced by selective D4 antagonists but was displaced by the selective 5-HT2A antagonist MDL100907. Using [3H]ketanserin as a 5-HT2A ligand, nemonapride showed high affinity for monkey (Ki = 10.4 nM) and cloned human (Ki = 9.4 nM) 5-HT2A receptors, while its affinity for rat receptors was lower (Ki = 140 nM). The present study demonstrates that cerebral cortical D4-like binding sites labeled by [3H]nemonapride in nonhuman primates consist of a very small portion of D4, but a substantial portion of 5-HT2A receptors. The unexpectedly high affinity of nemonapride for primate 5-HT2A receptor suggests reconsidering previous data from other studies using [3H]nemonapride, particularly those on D4-like receptors.


Subject(s)
Benzamides/metabolism , Cerebral Cortex/metabolism , Receptors, Dopamine D2/metabolism , Receptors, Serotonin/metabolism , Animals , Anisoles/pharmacology , Benzamides/pharmacology , Binding Sites/drug effects , Cerebral Cortex/drug effects , Dopamine Antagonists/metabolism , Dopamine D2 Receptor Antagonists , Humans , Ketanserin/metabolism , Ketanserin/pharmacology , Ligands , Macaca fascicularis , Pindolol/pharmacology , Piperazines/pharmacology , Propylamines/pharmacology , Receptor, Serotonin, 5-HT2A , Receptors, Dopamine D4 , Sulfonamides/pharmacology , Tritium
SELECTION OF CITATIONS
SEARCH DETAIL